Poland's Science Slump: Economic Boom Leaves Research Behind

Poland's economy is booming, but its science is dying. While GDP surges at over 4% annually, research investment stagnates at around 1.2% of GDP for the past decade. What does this mean for global health innovation and the longevity of its citizens?

The Science

According to data from Nature and Eurostat, Poland invests only 1.2% of its GDP in research and development (R&D), far below the EU average of 2.2% and countries like Germany at 3.1% or Sweden at 3.4%. This gap translates into fewer scientific publications, patents, and clinical trials. In 2025, Poland filed only 1,200 patents with the European Patent Office, compared to Germany's 14,000. The lack of funding directly impacts biomedicine, neuroscience, and public health, where progress requires sustained investment.

Polish scientists face low salaries (40% below the EU average) and temporary contracts that create job instability. According to a survey by the Polish Academy of Sciences, 30% of researchers consider emigrating to countries with better conditions, such as Germany, the UK, or the US. This brain drain weakens the country's ability to innovate in medical treatments and health technologies. For instance, Poland produces less than 1% of global life sciences publications despite a population of 38 million and a scientific tradition that includes figures like Marie Curie. In the longevity field, the lack of investment hampers the development of anti-aging therapies and regenerative medicine, areas where the country could have competitive advantages due to its strong base in chemistry and biology.

“Without sustained investment in science, the well-being of future generations is at risk. Public health and longevity depend on discoveries that are only possible with adequate funding.”

Key Findings

• Insufficient investment: Poland spends only 1.2% of GDP on R&D, compared to the EU average of 2.2% and Germany's 3.1%. This amounts to about €12 billion annually, less than half of what would be needed to reach the EU average.
• Brain drain: 30% of Polish researchers consider emigrating due to lack of opportunities, and 15% have already worked abroad. The most affected are young PhDs under 35.
• Low scientific output: Poland contributes less than 1% of global life sciences publications, and its relative impact (citations per article) is below the world average.
• Limited clinical trials: The number of clinical trials per million inhabitants is half the European average (12 vs. 24). This delays access to new treatments for diseases like cancer and neurodegenerative disorders.
• Technological dependence: 70% of medical technology used in Poland is imported, increasing healthcare costs and limiting local innovation.

Why It Matters

Science is the foundation of health advances. Without research, there are no new drugs, therapies, or wellness protocols. Countries like Poland, with a growing economy, have the opportunity to invest in preventive health and longevity. The lack of investment not only hampers medical progress but also increases dependence on foreign technologies, raising costs and reducing health sovereignty. For example, during the COVID-19 pandemic, Poland relied almost entirely on imported vaccines, while countries with higher R&D investment, like Germany, developed their own.

For biohackers and health enthusiasts, this means less local innovation in supplements, wearable devices, and cold/heat therapies. Polish science could be leading in areas like regenerative medicine, nutrigenomics, or cryotherapy, but without funds, those promises fade. A recent study from the University of Warsaw showed that 80% of Polish biotech startups fail within the first three years due to lack of funding, compared to 50% in the US.

Moreover, low R&D investment has direct implications for longevity. Without basic research on aging biology, it is difficult to develop interventions that delay age-related diseases. Poland has a rapidly aging population: by 2040, 30% of citizens are expected to be over 65. Investing in science now could reduce future healthcare costs and improve quality of life for the elderly.

Your Protocol

If you are a researcher, student, or simply a science advocate, you can act to drive change:

1. 1Support outreach: Share data on the importance of R&D investment on social media and with your political representatives. Use hashtags like #ScienceForPoland and #R&DInvestment. Organize talks in schools and universities to raise awareness among the next generation.
2. 2Consider international collaboration: Seek partners in countries with higher funding for joint projects. Programs like Horizon Europe offer funds for international consortia. Collaborating with German or Swedish institutions can open doors to resources and expertise.
3. 3Participate in clinical trials: If you live in Poland, enroll in local studies to increase the visibility of national research. You can search for trials on registries like ClinicalTrials.gov or at university hospitals. Your participation not only contributes to science but also gives you access to cutting-edge treatments.
4. 4Push for political change: Write to your MPs and senators to support increases in the R&D budget. Propose that Poland commit to reaching 2% of GDP by 2030, as other regional countries like Estonia (2.1%) have done.
5. 5Invest in citizen science: Participate in open science projects, such as genetic mapping of the Polish population or longevity studies. Platforms like Zooniverse allow contributions from home.

What To Watch Next

The European Union has launched Horizon Europe, allocating €95.5 billion for research until 2027. Poland could access these funds if it improves its scientific infrastructure and reduces bureaucracy. So far, Poland has only captured 1.5% of Horizon 2020 funds, far below its potential. Additionally, citizen initiatives like "Science for All" are pushing the government to increase the R&D budget to 2% of GDP by 2030. There are also movements in the European Parliament to link cohesion funds with R&D investment, which could benefit Poland.

In the private sector, some Polish companies are starting to invest in R&D. For example, pharmaceutical company Polpharma has increased its research spending by 20% annually since 2023. However, private R&D investment in Poland is only 0.6% of GDP, compared to 1.5% in the EU. Fostering public-private partnerships could be a key solution.

The Bottom Line

Poland urgently needs to reverse the trend. Investing in science is not an expense; it is an investment in health and well-being. Without it, the country risks falling behind in the next wave of medical innovation, which includes gene therapies, personalized medicine, and longevity technologies. The decision lies with politicians, but citizen pressure can make a difference. The future of Polish health depends on it. As Polish Nobel laureate Wisława Szymborska said, "Science is the poetry of reality." It's time for Poland to write its own poem.